These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 21087480

  • 1. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
    Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.
    BMC Cancer; 2010 Nov 18; 10():631. PubMed ID: 21087480
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic implication of HER2 in advanced biliary tract cancer.
    Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
    Oncotarget; 2016 Sep 06; 7(36):58007-58021. PubMed ID: 27517322
    [Abstract] [Full Text] [Related]

  • 3. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
    Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.
    PLoS One; 2018 Sep 06; 13(1):e0191593. PubMed ID: 29352306
    [Abstract] [Full Text] [Related]

  • 4. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
    Nakamura J, Kohya N, Kai K, Ohtaka K, Hashiguchi K, Hiraki M, Kitajima Y, Tokunaga O, Noshiro H, Miyazaki K.
    Int J Oncol; 2010 Oct 06; 37(4):845-52. PubMed ID: 20811706
    [Abstract] [Full Text] [Related]

  • 5. EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance.
    Kim Y, Jee S, Kim H, Paik SS, Choi D, Yoo SH, Shin SJ.
    Oncologist; 2024 Aug 05; 29(8):e1051-e1060. PubMed ID: 38709907
    [Abstract] [Full Text] [Related]

  • 6. Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.
    Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, Ariizumi S, Yamamoto M, Kurosaki K, Shoda J.
    J Gastroenterol; 2015 Apr 05; 50(4):467-79. PubMed ID: 25112701
    [Abstract] [Full Text] [Related]

  • 7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 8. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM.
    Mol Oncol; 2017 Sep 15; 11(9):1130-1142. PubMed ID: 28544747
    [Abstract] [Full Text] [Related]

  • 9. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.
    Neoplasia; 2012 Feb 15; 14(2):121-30. PubMed ID: 22431920
    [Abstract] [Full Text] [Related]

  • 10. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
    Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J, Kiguchi K.
    J Hepatol; 2012 Jul 15; 57(1):84-91. PubMed ID: 22326466
    [Abstract] [Full Text] [Related]

  • 11. EGFR and HER2 expression in advanced biliary tract cancer.
    Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG.
    World J Gastroenterol; 2009 Sep 28; 15(36):4511-7. PubMed ID: 19777609
    [Abstract] [Full Text] [Related]

  • 12. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD.
    Cancer; 2021 Apr 15; 127(8):1293-1300. PubMed ID: 33289918
    [Abstract] [Full Text] [Related]

  • 13. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug 15; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
    Cavalloni G, Peraldo-Neia C, Sarotto I, Gammaitoni L, Migliardi G, Soster M, Marchiò S, Aglietta M, Leone F.
    Mol Cancer Ther; 2012 Jul 15; 11(7):1528-38. PubMed ID: 22452946
    [Abstract] [Full Text] [Related]

  • 15. Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
    Feng F, Cheng Q, Zhang D, Li B, Qin H, Xu C, Han M, Yu Y, Li Z, Li JY, Qiu Z, Xiong L, Liu C, Li F, Yi B, Jiang X.
    Oncol Rep; 2020 Apr 15; 43(4):1089-1102. PubMed ID: 32323774
    [Abstract] [Full Text] [Related]

  • 16. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
    Singla S, Pippin JA, Drebin JA.
    Oncol Rep; 2012 Dec 15; 28(6):2211-6. PubMed ID: 23007710
    [Abstract] [Full Text] [Related]

  • 17. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    Borrero-García LD, Del Mar Maldonado M, Medina-Velázquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S.
    BMC Cancer; 2021 Jun 01; 21(1):652. PubMed ID: 34074257
    [Abstract] [Full Text] [Related]

  • 18. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A.
    BMC Cancer; 2010 May 11; 10():188. PubMed ID: 20459769
    [Abstract] [Full Text] [Related]

  • 19. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM.
    J Gastroenterol Hepatol; 2014 May 11; 29(5):1119-25. PubMed ID: 24372748
    [Abstract] [Full Text] [Related]

  • 20. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer.
    Hiraoka N, Nitta H, Ohba A, Yoshida H, Morizane C, Okusaka T, Nara S, Esaki M, Kishi Y, Shimada K.
    Hum Pathol; 2020 Nov 11; 105():9-19. PubMed ID: 32891647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.